Table 1.
Clinical and laboratory features of 464 patients with WHO-defined MF, stratified by presence or absence of RAS/CBLMT
| Variable | All patients (N = 464) | RAS/CBLWT (n = 405; 87%) | RAS/CBLMT (n = 59; 13%) | P (RAS/CBLWT vs RAS/CBLMT) |
|---|---|---|---|---|
| WHO 2016 diagnosis, n (%) | ||||
| Overt PMF | 155 (33) | 120 (30) | 35 (58) | <.0001 |
| Pre-PMF | 132 (29) | 120 (30) | 12 (20) | |
| Post-PV/ET MF | 177 (38) | 165 (40) | 12 (22) | |
| Male sex, n (%) | 277 (60) | 236 (58) | 41 (69) | .10 |
| Age at diagnosis, median (range), y | 60 (18-90) | 60 (18-90) | 64 (24-88) | .0235 |
| Age at diagnosis >65 y, n (%) | 172 (37) | 145 (36) | 27 (46) | .14 |
| Leukocytes, median (range), ×109/L [412] | 8.9 (0.6-250) | 8.8 (0.6-250) | 11.7 (2.1-90.8) | .08 |
| Leukocytes >25 × 109/L, n (%) | 42 (10) | 30 (8) | 12 (23) | .0010 |
| Hemoglobin, median (range), g/dL [415] | 11.9 (4.2-17.5) | 12 (4.2-17.5) | 10.6 (5.4-17.3) | .0016 |
| Hemoglobin <10 g/dL, n (%) | 99 (24) | 79 (22) | 20 (39) | .0060 |
| RBC transfusion dependence, n (%) [462] | 141 (31) | 111 (28) | 30 (52) | .0002 |
| Platelets, median (range), ×109/L [417] | 354 (10-1800) | 370 (10-1800) | 270 (14-1635) | .0031 |
| Platelets <100 × 109/L, median (range) | 41 (10) | 32 (9) | 9 (18) | .0454 |
| Peripheral CD34+, median (range), % [335] | 0.3 (0-22.2) | 0.3 (0-22.2) | 1.2 (0-16.7) | .0003 |
| PB blasts, median (range), % [426] | 0 (0-18) | 0 (0-18) | 1 (0-16) | <.0001 |
| PB blasts ≥1%, n (%) | 105 (25) | 79 (21) | 26 (48) | <.0001 |
| PB blasts ≥5%, n (%) | 14 (3) | 6 (2) | 8 (15) | <.0001 |
| BM fibrosis grade ≥2, median (range) [438] | 301 (69) | 258 (67) | 43 (80) | .06 |
| Splenomegaly, n (%) [428] | 348 (81) | 299 (80) | 49 (88) | .20 |
| Constitutional symptoms, n (%) [463] | 172 (37) | 141 (35) | 31 (53) | .0088 |
| Extramedullary hematopoiesis, n (%) [449] | 19 (4) | 13 (3) | 6 (10) | .0132 |
| IPSS risk stratification, n (%) [400] | ||||
| Low risk | 118 (29) | 112 (32) | 6 (12) | Reference |
| Intermediate-1 risk | 127 (32) | 117 (34) | 10 (20) | .38 |
| Intermediate-2 risk | 78 (20) | 61 (17) | 17 (33) | .0004 |
| High risk | 77 (19) | 59 (17) | 18 (35) | .0001 |
| DIPSS risk stratification, n (%) [400] | ||||
| Low risk | 118 (29) | 112 (32) | 6 (12) | Reference |
| Intermediate-1 risk | 175 (44) | 156 (45) | 19 (37) | .08 |
| Intermediate-2 risk | 87 (22) | 67 (19) | 20 (39) | .0001 |
| High risk | 20 (5) | 14 (4) | 6 (12) | .0003 |
| MIPSS70 risk stratification, n (%) [382] | ||||
| Low risk | 84 (22) | 82 (24) | 2 (4) | Reference |
| Intermediate risk | 196 (51) | 179 (54) | 17 (36) | .06 |
| High risk | 102 (60) | 73 (22) | 29 (60) | <.0001 |
| Deaths, n (%) [463] | 172 (37) | 126 (31) | 46 (78) | <.0001 |
| Leukemic transformation, n (%) [463] | 57 (12) | 36 (10) | 21 (36) | <.0001 |
Bold P values indicate statistically significant results. The numbers in brackets indicate the number of patients with evaluable data.
BM, bone marrow; RBC, red blood cell.